Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D In Brief: Lilly’s Cyramza Cleared In Lung, SABCS & ASH Updates

Executive Summary

Lilly adds significant new market for ramucirumab, while early data presented at San Antonio Breast Cancer Symposium and American Society of Hematology annual meeting pave the way for future filings.

You may also be interested in...



Lilly’s Cyramza Shows Promise In First-Line NSCLC – But Not Much Room To Grow

Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?

Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta

I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.

Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?

The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel